{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007059","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.748103+00:00","generated_at":"2026-06-26T01:33:01.987168+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulgent Genetics Q1 revenue $320.3M, core revenue up 59%, raises FY outlook to $660M","bullets":["Revenue $320.3M (down from $359.4M Q1 2021); GAAP net income $154M ($4.93/share).","Core revenue ex-COVID NGS $25.1M (+59% YoY); billable tests ~3.2M vs 3.8M.","Non-GAAP net income $158.7M ($5.08/share); Adjusted EBITDA $213.5M.","Raises FY 2022 revenue outlook to $660M from $600M; core revenue outlook to $180M from $175M.","Cash & investments $1.1B at March 31; closed $170M acquisition of Inform Diagnostics on April 26."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007059","json":"https://secwatch.observer/filing/0000950170-22-007059.json","markdown":"https://secwatch.observer/filing/0000950170-22-007059.md","text":"https://secwatch.observer/filing/0000950170-22-007059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022007059/0000950170-22-007059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022007059/flgt-20220503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:33:01.987168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}